![Single digits: Black, Hispanic scientists strikingly underrepresented at NCI among senior workforce and grantees](https://cdn.cancerletter.com/media/2021/07/02150855/47-26-pie-4x3-1.jpg)
![Single digits: Black, Hispanic scientists strikingly underrepresented at NCI among senior workforce and grantees](https://cdn.cancerletter.com/media/2021/07/02150855/47-26-pie-4x3-1.jpg)
Cover Story
FreeHealth Equity
A recent analysis of the National Cancer Institute’s workforce and grant recipients shows that Black and Hispanic scientists are dramatically underrepresented across key metrics, both intramural and extramural.
In Brief
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for July 2021
The National Cancer Institute approved the following clinical research studies last month. Â For further information, contact the principal investigator listed.
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- Tweaking the existing systems is not the answer to drug shortages